Veterinary Anthrax Vaccines Market Size, Share, Growth, and Industry Analysis, By Type (Cell Free PA Vaccines and Live Vaccines), By Application (Cow, Sheep, Swine, and Other), Regional Insights and Forecast From 2025 To 2033

• 

  Request a Free sample to learn more about this report

VETERINARY ANTHRAX VACCINES MARKET OVERVIEW

The global veterinary anthrax vaccines market was valued at USD 0.04 billion in 2024 and is projected to reach USD 0.05 billion in 2025, steadily progressing to USD 0.08 billion by 2033, with a CAGR of 7.6% from 2025 to 2033.

Veterinary anthrax vaccines are vaccines designed to protect animals, particularly livestock, from anthrax, a bacterial disease caused by Bacillus anthracis. Anthrax can affect a wide range of animals, including cattle, sheep, goats, horses, and more. It is a zoonotic disease, meaning it can also infect humans who come into contact with infected animals or contaminated animal products.

Anthrax vaccines for animals are crucial for preventing the spread of the disease within livestock populations and minimizing the risk of transmission to humans. The vaccines work by stimulating the animal's immune system to produce antibodies against the bacteria, providing protection against anthrax infection. The choice of vaccine depends on various factors, including the specific animal species, the prevalence of anthrax in the area, and the available resources for vaccination campaigns. In areas where anthrax is endemic or where there's a history of outbreaks, vaccination of livestock can be an essential component of anthrax control measures.

COVID-19 IMPACT

Focus on Zoonotic Diseases to Hamper Demand Significantly

The COVID-19 pandemic has been unprecedented and staggering, with veterinary anthrax vaccines experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

COVID-19 pandemic had a life changing impact globally. The veterinary anthrax vaccines market was significantly affected. The virus had various impacts on different markets. Lockdowns were imposed in several nations. This unpredictable pandemic caused disruptions on several sorts of businesses. Restrictions tightened during the pandemic due to increasing number of cases. Numerous industries were affected. However, the market for veterinary anthrax vaccines experienced a reduced demand.

The COVID-19 pandemic highlighted the importance of zoonotic diseases (diseases that can be transmitted between animals and humans). This focus on zoonoses might lead to increased attention and resources for preventing and managing diseases like anthrax that can impact both animals and humans. Restrictions on travel and movement could affect the ability of veterinary professionals to carry out fieldwork, including vaccination campaigns in remote or rural areas.

The pandemic has strained healthcare resources, including personnel, facilities, and funding. This could potentially affect the availability of resources for veterinary health programs, including vaccination campaigns. During a pandemic, public health priorities often shift towards human health and safety. This might affect the allocation of resources and attention to animal health and vaccination efforts. The market is anticipated to boost the veterinary anthrax vaccines market share following the pandemic.

LATEST TRENDS

Advanced Vaccine Formulations to Broaden Market Growth

Researchers might have continued to develop improved vaccine formulations, including safer and more effective options. This could involve refining inactivated vaccines, recombinant protein-based vaccines, or other innovative approaches. Advances in biotechnology and vaccine development techniques might have led to the adoption of newer technologies such as synthetic biology, gene editing, and advanced adjuvants to enhance the efficacy and safety of veterinary anthrax vaccines.

The concept of "One Health" emphasizes the interconnectedness of human, animal, and environmental health. As a zoonotic disease, anthrax could have received attention within the context of this approach, leading to coordinated efforts to control the disease in both animals and humans. These latest developments are anticipated to boost the veterinary anthrax vaccines market share.

Request a Free sample to learn more about this report

VETERINARY ANTHRAX VACCINES MARKET SEGMENTATION

By Type

Based on type, the market is divided into Cell Free PA Vaccines and Live Vaccines.

Cell Free PA Vaccines holds a major share of the global market.

By Application

Based on application, the market is bifurcated into Cow, Sheep, Swine, and Other.

Cow as application holds a major share of the global market.

DRIVING FACTORS

Animal Welfare and Livestock Health in Use to Boost Market Share

Anthrax can cause severe illness and death in livestock, including cattle, sheep, goats, and others. Vaccination helps protect animals from suffering and death due to the disease, thereby safeguarding animal welfare and the livelihoods of farmers and herders. Anthrax outbreaks among animals can lead to contaminated animal products, such as meat, hides, and wool, which can transmit the disease to humans. Veterinary anthrax vaccines help mitigate this risk by reducing the prevalence of the disease in animal populations.

Preventing Economic Losses to Boost Market Size

Anthrax outbreaks can result in economic losses due to livestock deaths, trade restrictions, and disruption of agricultural activities. Vaccination programs can help minimize these losses by preventing disease spread and maintaining livestock productivity. Anthrax is a disease that can be transmitted from animals to humans. This zoonotic potential underscores the importance of controlling the disease in animals to prevent human infections. Veterinary anthrax vaccines play a crucial role in breaking the transmission cycle and reducing the risk of human exposure. These factors are anticipated to drive the veterinary anthrax vaccines market share.

RESTRAINING FACTORS

Public Awareness and Education to Hamper Market Share

Lack of awareness and understanding of anthrax and the importance of vaccination among livestock owners, farmers, and communities can result in low demand for vaccines. In some regions, there might be challenges in accessing high-quality veterinary anthrax vaccines due to limited supply chains, distribution networks, or regulatory barriers. Lack of financial resources, infrastructure, and trained personnel can hinder the implementation of effective vaccination programs, especially in low-income or resource-constrained areas. The factors are anticipated to hinder the growth of the veterinary anthrax vaccines market share.

• Request a Free sample to learn more about this report

•  

VETERINARY ANTHRAX VACCINES MARKET REGIONAL INSIGHTS

North America Dominates the Veterinary Anthrax Vaccines Market

North America is the largest market shareholder for veterinary anthrax vaccines market share. The region has well-developed economies with significant resources dedicated to agriculture, including livestock farming. This economic strength can facilitate investment in veterinary healthcare, including vaccine research, development, and distribution. North America has established veterinary healthcare infrastructure, research institutions, and regulatory frameworks that support the development and distribution of veterinary vaccines. Europe is the second major shareholder for the growth of the veterinary anthrax vaccines market share.

KEY INDUSTRY PLAYERS

Market Players Focus on New Product Launches to Strengthen Market Position

Leading players in the market are adopting various strategies to expand their presence in the market. These include R&D investments and launch of new, technologically-advanced products in the market. Some companies are also adopting strategies such as partnerships, mergers, and acquisitions to strengthen their market position.   

List of Top Veterinary Anthrax Vaccines Companies

• Godrej Agrovet [India]
• Bayer Sanidad Animal [Germany]
• Biogenesis Bago SA [Argentina]
• Botswana Vaccine Institute [Botswana]
• Central Veterinary Control and Research Institute [Egypt]
• Centro Diagnostico Veterinario [Brazil]
• Ceva Sante Animale [France]
• Colorado Serum Company [U.S.]
• Empresa Colombiana de Productos Veterinarios S.A [Colombia]
• Indian Immunologicals Limited [India]
• Institute for Biological Products [Afghanistan]
• Intervac (PVT) Ltd [Pakistan]
• JOVAC [U.S.]

REPORT COVERAGE

This research profiles a report with extensive studies that take into description of the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics changes.